1. Home
  2. Stocks
  3. Glaxo Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • Similar Stocks
  • FAQs

    • GlaxoSmithKline Pharmaceuticals Share Price

    Large Cap
    ₹2,594.35
    -30.55 (-1.16%)
    05 November, 2024 21:56 BSE: 500660 NSE: GLAXO ISIN: INE159A01016

    Start SIP in GlaxoSmithKline Pharmaceuticals

    Start SIP

    GlaxoSmithKline Pharmaceuticals Performance

    Day Range

    • Low 2,590
    • High 2,659
    ₹ 2,594

    52 Week Range

    • Low 1,408
    • High 3,088
    ₹ 2,594
    • Open Price2,637
    • Previous Close2,625
    • Volume148156

    GlaxoSmithKline Pharmaceuticals Chart

    • Over 1 Month -5.71%
    • Over 3 Month -8.01%
    • Over 6 Month + 23.81%
    • Over 1 Year + 84.63%

    GlaxoSmithKline Pharmaceuticals Key Statistics

    P/E Ratio 65.1
    PEG Ratio 15.5
    Market Cap Cr 43,950
    Price to Book Ratio 24.7
    EPS 38.4
    Dividend 1.2
    Relative Strength Index 41.81
    Money Flow Index 48
    MACD Signal -28.22
    Average True Range 99.39

    Glaxosmithkline Pharmaceuticals Investment Rating

    • Master Rating:

    • GlaxoSmithKline Pharmaceuticals Ltd., based in Mumbai, manufactures and distributes prescription medicines across therapeutic areas like dermatology, diabetes, and cardiovascular diseases. It also offers vaccines for hepatitis, influenza, chickenpox, and other infectious diseases in India and global markets. Glaxosmithkline Pharms. has an operating revenue of Rs. 3,560.48 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 24% is great, ROE of 33% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 11% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 89 which is a GOOD score indicating consistency in earnings, a RS Rating of 62 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    GlaxoSmithKline Pharmaceuticals Financials
    IndicatorSep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,000811911805953738782
    Operating Expenses Qtr Cr 681582656587667597615
    Operating Profit Qtr Cr 319229255218287141167
    Depreciation Qtr Cr 17161817181617
    Interest Qtr Cr 0010001
    Tax Qtr Cr 90677620814856
    Net Profit Qtr Cr 24918219345216131131
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 3,5313,318
    Operating Expenses Annual Cr 2,5072,417
    Operating Profit Annual in Cr 901799
    Depreciation Cr 7066
    Interest Annual Cr 22
    Tax Annual Cr 224228
    Net Profit Annual Cr 585608
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 579488
    Cash from Investing Activity Annual Cr 15805
    Cash from Financing Annual Activity Cr -562-1,544
    Net Cash Flow Annual Cr 32-251
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 1,7841,753
    Fixed Assets Annual Cr 335350
    Total Non Current Assets Annual Cr 782861
    Total Current Assets Annual Cr 2,7662,467
    Total Assets Annual Cr 3,5483,328
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 105103
    ROE Annual % 3335
    ROCE Annual % 4742
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3028
    IndicatorSep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,011815930805957762787
    Operating Expenses Qtr Cr 689584673587668618618
    Operating Profit Qtr Cr 322231257218289144170
    Depreciation Qtr Cr 17161817181617
    Interest Qtr Cr 0010001
    Tax Qtr Cr 91677620824957
    Net Profit Qtr Cr 25318219446218132133
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 3,5763,352
    Operating Expenses Annual Cr 2,5452,447
    Operating Profit Annual in Cr 909804
    Depreciation Cr 7066
    Interest Annual Cr 22
    Tax Annual Cr 226229
    Net Profit Annual Cr 594617
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 582484
    Cash from Investing Activity Annual Cr 9808
    Cash from Financing Annual Activity Cr -562-1,543
    Net Cash Flow Annual Cr 29-251
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 1,7781,741
    Fixed Assets Annual Cr 335350
    Total Non Current Assets Annual Cr 758832
    Total Current Assets Annual Cr 2,7982,494
    Total Assets Annual Cr 3,5573,327
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 105103
    ROE Annual % 3335
    ROCE Annual % 4742
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3028
    Invest in GlaxoSmithKline Pharmaceuticals

    GlaxoSmithKline Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹2,594.35
    -30.55 (-1.16%)
    pointer
    • Bullish Moving Average
    • ___
    • 3
    • Bearish Moving Average
    • ___
    • 13
    • 20 Day
    • ₹2,668.28
    • 50 Day
    • ₹2,700.17
    • 100 Day
    • ₹2,643.24
    • 200 Day
    • ₹2,441.58
    • 20 Day
    • ₹2,671.80
    • 50 Day
    • ₹2,735.06
    • 100 Day
    • ₹2,719.26
    • 200 Day
    • ₹2,443.84

    GlaxoSmithKline Pharmaceuticals Resistance and Support

    PIVOT
    ₹2,614.44
    Resistance
    First Resistance 2,638.87
    Second Resistance 2,683.38
    Third Resistance 2,707.82
    RSI 41.81
    MFI 48.00
    MACD Single Line -28.22
    MACD -25.44
    Support
    First Support 2,569.92
    Second Support 2,545.48
    Third Supoort 2,500.97

    GlaxoSmithKline Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 150,995 9,490,036 62.85
    Week 120,615 6,200,797 51.41
    1 Month 106,161 5,466,216 51.49
    6 Month 155,762 7,210,239 46.29

    GlaxoSmithKline Pharmaceuticals Result Highlights

    GlaxoSmithKline Pharmaceuticals Synopsis

    NSE-Medical-Diversified

    GlaxoSmithKline Pharmaceuticals Ltd. is a leading pharmaceutical company in India, specializing in the manufacturing, distribution, and trading of prescription medicines and vaccines. Its product portfolio covers a wide range of therapeutic areas, including anti-infectives, dermatology, gynecology, diabetes, cardiovascular, and respiratory diseases. The company's vaccines help prevent various infectious diseases such as hepatitis A and B, influenza, chickenpox, diphtheria, cervical cancer, and more. GlaxoSmithKline Pharmaceuticals has a strong presence in India and globally. With a focus on improving health outcomes, it provides innovative and effective medical solutions to a broad spectrum of patients.
    Market Cap 44,467
    Sales 3,527
    Shares in Float 4.24
    No of funds 335
    Yield 1.62
    Book Value 24.79
    U/D Vol ratio 0.8
    LTDebt / Equity
    Alpha 0.2
    Beta 0.69

    GlaxoSmithKline Pharmaceuticals Shareholding Pattern

    Owner NameSep-24Jun-24Mar-24Dec-23
    Promoters 75%75%75%75%
    Mutual Funds 4.98%4.71%4.51%4.5%
    Insurance Companies 2.27%2.67%3.25%4.02%
    Foreign Portfolio Investors 4.36%4.02%3.48%2.93%
    Financial Institutions/ Banks 0.01%0.01%0.01%0.01%
    Individual Investors 10.97%11.15%11.27%11.08%
    Others 2.41%2.44%2.48%2.46%

    GlaxoSmithKline Pharmaceuticals Management

    Name Designation
    Ms. R S Karnad Chairperson
    Mr. B Akshikar Managing Director
    Mr. J Chandy WholeTime Director & CFO
    Mr. S Williams Non Executive Director
    Mr. M Anand Independent Director
    Dr.(Ms.) S Maheshwari Independent Director
    Mr. A N Roy Independent Director
    Mr. D Sundaram Independent Director
    Mr. P V Bhide Independent Director

    GlaxoSmithKline Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    GlaxoSmithKline Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2024-10-29 Quarterly Results & Interim Dividend
    2024-08-02 Quarterly Results
    2024-05-17 Audited Results & Final Dividend
    2024-02-12 Quarterly Results
    2023-11-09 Quarterly Results
    Date Purpose Remarks
    2024-11-07 INTERIM Rs.12.00 per share(120%)Interim Dividend
    2024-05-31 FINAL Rs.32.00 per share(320%)Final Dividend
    2023-06-30 FINAL Rs.32.00 per share(320%)Final Dividend
    2022-07-08 FINAL Rs.30.00 per share(300%)Dividend
    2022-07-08 SPECIAL Rs.60.00 per share(600%)Special Dividend

    GlaxoSmithKline Pharmaceuticals FAQs

    What is Share Price of GlaxoSmithKline Pharmaceuticals ?

    GlaxoSmithKline Pharmaceuticals share price is ₹2,594 As on 05 November, 2024 | 21:42

    What is the Market Cap of GlaxoSmithKline Pharmaceuticals ?

    The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹43949.8 Cr As on 05 November, 2024 | 21:42

    What is the P/E ratio of GlaxoSmithKline Pharmaceuticals ?

    The P/E ratio of GlaxoSmithKline Pharmaceuticals is 65.1 As on 05 November, 2024 | 21:42

    What is the PB ratio of GlaxoSmithKline Pharmaceuticals ?

    The PB ratio of GlaxoSmithKline Pharmaceuticals is 24.7 As on 05 November, 2024 | 21:42

    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

    Q2FY23

    5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Mutual Fund, Mutual Fund-SIP are not Exchange traded products, and the Member is just acting as distributor. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.